99 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
, accidental death due to food seeking behavior). In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parent
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
the Participant’s termination as the result of the Participant’s death or Disability, the Participant may exercise his or her Option within … .
(iv) Death of Participant. If a Participant dies while a Service Provider, the Option may be exercised following the Participant’s death within
424B5
sct24md
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
kzoyykm26m0psa4c4
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
dvuglhe6 4zw2ft48
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
y6meyykrfdb2syaw
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
2zscfpdke 65p1f66
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
kqs5tg 8k
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
ke502 2745b88rg
3 May 23
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
5:26pm
8-K
EX-99.1
izrw70shocb9kmho3vn
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
3kk2w8iyk0jq7 vaxgq4
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.1
chm0chuso6 5a2hwh
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
8-K
EX-99.1
7n3jejfpq0mrl5
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
ksyg9exdzgu
20 Jul 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:01am
8-K
EX-99.1
dne45 37qv3
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm